Stifel Nicolaus raised Rocket Lab's (RKLB) price target to $105, suggesting nearly 21% upside, while Morgan Stanley also upgraded RKLB to Overweight with the same target. Cantor Fitzgerald maintained an $85 target, citing over 84 successful missions. These analyst ratings reflect growing confidence in Rocket Lab’s recent performance and mission success.
A blockchain investigator has accused RaveDAO of knowing the identity of the individual who manipulated its token’s price. The sleuth pointed to suspicious exchange-linked activity as RAVE’s market cap surged from $60 million to $6 billion and then declined again. The investigation highlights concerns over potential market manipulation within the decentralized autonomous organization.
KuCoin has expanded its PROOF trading campaign starting April 20, adding new trading competitions and a reward pool of up to $500,000. The campaign aims to boost user engagement and trading activity on the platform. Details of the competitions and how users can participate are expected to be announced soon, with the increased rewards highlighting KuCoin’s ongoing efforts to incentivize traders.
Enveric Biosciences stock surged over 160% after President Trump signed an executive order to fast-track psychedelic drug reviews. The move also included a $50 million fund for ibogaine research, boosting biotech stocks in the psychedelic sector. ENVB’s rally marks a major shift in the psychedelics market driven by regulatory support.
Chiliz's CHZ token surged 10% on April 20, driven by plans to expand into the U.S. sports market. The price spike has reignited trader interest, reflecting growing optimism about Chiliz's strategic move. The company aims to leverage the U.S. market to boost its presence in the Web3 sports and entertainment sectors, fueling positive sentiment around CHZ.
The International Energy Agency (IEA) warns that the US naval blockade of the Strait of Hormuz increases global energy market instability, potentially affecting oil prices and economic stability over the next two years. The strategic move heightens concerns about supply disruptions in a critical oil transit route, with significant implications for markets and energy security.
Definium Therapeutics (DFTX) stock reached a 52-week high, rising over 13% in premarket trading after President Trump signed an executive order supporting psychedelic medicine research. The order directs the FDA to expedite research and approval processes for psychedelic treatments targeting mental health disorders, including GAD. The company's CEO praised the move, emphasizing its potential impact on their DT120 program.